Quantcast
Last updated on April 24, 2014 at 11:39 EDT

Latest Opioid Stories

2013-08-27 23:29:33

Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic non-cancer pain. Birmingham, Alabama (PRWEB) August 27, 2013 *To see if you qualify for this Constipation Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com) or contact us directly at (205) 380-6434. There is no cost...

2013-08-26 08:28:20

Clinical Study Also Indicates No Systemic Prodrug Exposure Over Multiple-Day Dosing at Maximum Daily Dose NORTH LIBERTY, Iowa, Aug. 26, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced positive results from one of several clinical and non-clinical studies that the company is performing in preparation for its New Drug Application (NDA) for KP201...

2013-08-07 12:27:04

DUBLIN, Ireland, August 7, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/33f35n/pain_therapeutics) has announced the addition of new report "Pain Therapeutics - Drugs, Markets and Companies [http://www.researchandmarkets.com/research/33f35n/pain_therapeutics ]" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report describes the latest concepts of pathomechanisms of pain as a basis...

2013-08-07 08:29:35

NORTH LIBERTY, Iowa, Aug. 7, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Method of Making and Use Thereof."...

2013-08-06 23:26:56

PAINWeek designates September 6 as “Opioid Safety Day,” and will present a 90-minute session, “The Great Divide: the Debate on Long-Term Opioid Prescribing for Chronic Noncancer Pain” at the national conference. The expert panel will offer an expansive discussion that addresses numerous perspectives in this ongoing controversy. Montclair, NJ (PRWEB) August 06, 2013 PAINWeek, the National Conference on Pain for Frontline Practitioners, has designated Friday, September 6, as...

2013-08-01 23:24:45

PAINWeek and the American Pain Society will offer REMS-compliant prescriber education for extended-release and long-acting opioids to all interested participants at no cost. Montclair, NJ (PRWEB) August 01, 2013 As an element of its focus on prescription analgesic safety, PAINWeek, the National Conference on Pain for Frontline Practitioners, today announced that the 2013 program agenda will include a 3-hour educational activity that complies with the FDA’s Risk Evaluation and Mitigation...

2013-07-29 16:25:56

NEWARK, Calif., July 29, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has acquired all United States and Canadian rights to Lazanda(®) (fentanyl) nasal spray from Archimedes Pharma Limited. Lazanda is indicated for the management of breakthrough pain in cancer patients (BTPc) 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. "Breakthrough pain is highly prevalent in...

2013-07-29 08:25:30

RALEIGH, N.C., July 29, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the regulatory approval of ONSOLIS in Taiwan for the management of breakthrough cancer pain in opioid tolerant, adult patients with cancer. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) In Taiwan, BDSI has licensed the commercialization rights to TTY Biopharm, where the product will be marketed under the brand name PAINKYL. TTY will be responsible...

2013-07-24 23:28:58

The American Pain Society (APS) will present a 3-hour REMS CME activity, along with a full-day track on chronic pain assessment and treatment at the PAINWeek 2013 National Conference. Montclair, NJ (PRWEB) July 24, 2013 PAINWeek, the National Conference on Pain for Frontline Practitioners, today announced that the American Pain Society (APS) will again contribute its expertise to the 2013 conference agenda, with the presentation of two all-new educational programs. On Thursday, September...

2013-07-23 08:31:42

CHARLESTON, S.C., July 23, 2013 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the completion of its scheduled Pre-IND meeting with the U.S Food and Drug Administration (FDA) for the proposed Investigational New Drug, CL-H1T, as a novel...